https://mindmedicinelaw.com/briefing/federal-report-urges-states-to-prepare-for-fda-psychedelic-approvals-20260904-38841The Psychedelic Journalen2026-09-04T22:04:30.448364+00:00Federal Report Urges States to Prepare for FDA Psychedelic Approvalsfederal psychedelic policy, FDA approval psychedelics, state law harmonization, clinical trial blinding, THC active placebo, mental health regulation, psychedelic infrastructure, regulatory readiness, MDMA psilocybin trialshttps://mindmedicinelaw.com/briefing/new-zealand-approves-mdma-for-ptsd-policy-and-clinical-implications-20260904-38842The Psychedelic Journalen2026-09-04T22:04:10.016650+00:00New Zealand Approves MDMA for PTSD: Policy and Clinical Implicationsmdma approval new zealand, ptsd treatment, psychedelic policy, clinical trials mdma, medsafe regulation, international drug policy, mental health innovation, adverse event monitoring, equity in psychedelic carehttps://mindmedicinelaw.com/briefing/va-psilocybin-trial-in-alabama-policy-and-clinical-implications-20260904-38672The Psychedelic Journalen2026-09-04T15:07:16.305977+00:00VA Psilocybin Trial in Alabama: Policy and Clinical Implicationsva psilocybin trial, alabama veterans mental health, psychedelic clinical research, federal policy on psychedelics, treatment-resistant ptsd, psychedelic therapy risks, veterans affairs research, conservative state drug policy, psilocybin-assisted therapy, clinical trial diversityhttps://mindmedicinelaw.com/briefing/md-anderson-launches-psilocybin-trial-for-chemotherapy-neurotoxicity-20260904-38673The Psychedelic Journalen2026-09-04T15:06:33.520945+00:00MD Anderson Launches Psilocybin Trial for Chemotherapy Neurotoxicitypsilocybin, chemotherapy-induced neurotoxicity, MD Anderson Cancer Center, clinical trials, oncology supportive care, FDA regulation, psychedelic research, peripheral neuropathy, neuroprotection, drug-drug interactionshttps://mindmedicinelaw.com/briefing/new-zealand-approves-mdma-therapy-for-severe-ptsd-policy-and-practice-20260904-38670The Psychedelic Journalen2026-09-04T15:06:06.095378+00:00New Zealand Approves MDMA Therapy for Severe PTSD: Policy and Practicemdma approval new zealand, ptsd treatment policy, psychedelic-assisted therapy, medsafe regulation, asia-pacific drug policy, clinical trial data mdma, post-market surveillance, mental health innovationhttps://mindmedicinelaw.com/briefing/11-hsd-enzymes-and-ptsd-implications-for-neurobiology-and-future-psychiatric-tri-20260903-38592The Psychedelic Journalen2026-09-04T22:05:23.931422+00:0011β-HSD Enzymes and PTSD: Implications for Neurobiology and Future Psychiatric Trials11β-hsd, glucocorticoid metabolism, ptsd, psychiatric drug development, biomarkers, clinical trial design, neuroimaging, trauma research, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/drosophila-models-illuminate-sleep-impairments-in-stimulant-use-disorder-researc-20260903-38568The Psychedelic Journalen2026-09-04T22:04:59.513440+00:00Drosophila Models Illuminate Sleep Impairments in Stimulant Use Disorder Researchdrosophila models, stimulant use disorder, sleep impairment, dopamine system, preclinical neuroscience, psychedelic-assisted therapy, genetic pathways, translational research, pharmacological targetshttps://mindmedicinelaw.com/briefing/psilocybin-and-chemotherapy-nerve-injury-new-preclinical-data-from-ut-md-anderso-20260903-38844The Psychedelic Journalen2026-09-04T22:04:46.121531+00:00Psilocybin and Chemotherapy Nerve Injury: New Preclinical Data from UT MD Andersonpsilocybin, chemotherapy-induced neuropathy, preclinical research, supportive oncology, neuroprotection, translational neuroscience, drug policy, FDA regulation, psychedelic researchhttps://mindmedicinelaw.com/briefing/mdma-prescribing-approved-for-ptsd-u-s-policy-and-clinical-implications-20260903-38843The Psychedelic Journalen2026-09-04T22:03:47.652197+00:00MDMA Prescribing Approved for PTSD: U.S. Policy and Clinical Implicationsmdma approval, ptsd treatment, fda policy, psychiatric prescribing, drug rescheduling, clinical trials, risk evaluation, insurance coverage, psychedelic therapy, mental health regulationhttps://mindmedicinelaw.com/briefing/silent-synapse-activation-mechanisms-and-clinical-prospects-20260903-38593The Psychedelic Journalen2026-09-04T15:07:55.563945+00:00Silent Synapse Activation: Mechanisms and Clinical Prospectssilent synapse activation, neuroplasticity, depression, addiction, psychedelic research, clinical translation, AMPAR, NMDAR, optogenetics, brain imaginghttps://mindmedicinelaw.com/briefing/psychedelics-ketamine-and-cannabinoids-for-opioid-use-disorder-us-policy-and-cli-20260903-38548The Psychedelic Journalen2026-09-04T15:07:36.541041+00:00Psychedelics, Ketamine, and Cannabinoids for Opioid Use Disorder: US Policy and Clinical Evidence Reviewopioid use disorder, psychedelics, ketamine, cannabinoids, ibogaine, regulatory policy, clinical trials, safety, neuroplasticity, public healthhttps://mindmedicinelaw.com/briefing/donor-surge-reshapes-psychedelic-research-funding-in-us-20260903-38500The Psychedelic Journalen2026-09-03T22:04:23.820111+00:00Donor Surge Reshapes Psychedelic Research Funding in USpsychedelic research funding, FDA approval psychedelics, philanthropy in mental health, clinical trials psychedelics, research infrastructure, donor influence, access models, public health policy, MDMA therapy, US psychedelic policyhttps://mindmedicinelaw.com/briefing/bi-1569912-phase-1-results-glun2b-nam-safety-in-germany-japan-20260902-38594The Psychedelic Journalen2026-09-04T22:05:39.352486+00:00BI 1569912 Phase 1 Results: GluN2B NAM Safety in Germany & Japanbi 1569912, glun2b nmda modulator, phase 1 clinical trials, neuropsychiatric drug development, safety and tolerability, non-hallucinogenic cns therapeutics, germany, japan, pharmacokinetics, policy implicationshttps://mindmedicinelaw.com/briefing/ketamine-s-antidepressive-effects-in-refractory-bipolar-depression-clinical-tria-20260902-38674The Psychedelic Journalen2026-09-04T15:08:14.248430+00:00Ketamine’s Antidepressive Effects in Refractory Bipolar Depression: Clinical Trial Insightsketamine, bipolar depression, treatment-resistant mood disorders, clinical trials, FDA regulation, off-label use, antidepressant mechanisms, psychiatric safety, policy implications, real-world evidencehttps://mindmedicinelaw.com/briefing/psilocybin-therapy-for-cocaine-addiction-early-clinical-signals-in-the-u-s-20260902-38502The Psychedelic Journalen2026-09-03T22:04:36.470105+00:00Psilocybin Therapy for Cocaine Addiction: Early Clinical Signals in the U.S.psilocybin therapy, cocaine addiction, clinical trials, psychedelic-assisted therapy, FDA regulation, substance use disorder, public health policy, treatment efficacy, safety riskshttps://mindmedicinelaw.com/briefing/serial-iv-ketamine-for-bipolar-depression-ontario-rct-results-20260902-38253The Psychedelic Journalen2026-09-03T15:04:07.949692+00:00Serial IV Ketamine for Bipolar Depression: Ontario RCT Resultsketamine, bipolar depression, randomized controlled trial, treatment-resistant depression, mania risk, clinical guidelines, health policy, mood stabilizers, psychedelic research, canadahttps://mindmedicinelaw.com/briefing/subcutaneous-ketamine-for-treatment-resistant-depression-a-case-report-from-braz-20260901-38603The Psychedelic Journalen2026-09-04T22:05:52.156466+00:00Subcutaneous Ketamine for Treatment-Resistant Depression: A Case Report from Brazilsubcutaneous ketamine, treatment-resistant depression, case report, alternative delivery methods, clinical trials, psychiatric policy, Brazil, NMDA antagonist, public health accesshttps://mindmedicinelaw.com/briefing/mapping-human-thalamus-function-seeg-insights-for-psychedelic-research-20260901-38587The Psychedelic Journalen2026-09-04T15:08:31.459207+00:00Mapping Human Thalamus Function: SEEG Insights for Psychedelic Researchthalamus, stereoelectroencephalography, thalamo-cortical circuits, psychedelic research, neuromodulation, clinical trial design, epilepsy, functional brain mapping, direct electrical stimulation, translational neurosciencehttps://mindmedicinelaw.com/briefing/phase-1-results-oral-ketamir-2-safety-and-pk-in-neuropathic-pain-20260901-38588The Psychedelic Journalen2026-09-04T15:06:53.425441+00:00Phase 1 Results: Oral Ketamir-2 Safety and PK in Neuropathic Painketamir-2, nmda antagonist, phase 1 trial, oral formulation, neuropathic pain, safety profile, pharmacokinetics, non-opioid therapeutics, dissociative risk, clinical developmenthttps://mindmedicinelaw.com/briefing/psilocybin-and-neuroplasticity-in-trd-evidence-and-policy-outlook-20260901-38049The Psychedelic Journalen2026-09-03T15:04:18.307449+00:00Psilocybin and Neuroplasticity in TRD: Evidence and Policy Outlookpsilocybin, neuroplasticity, treatment-resistant depression, clinical trials, bdnf, regulatory policy, psychedelic therapy, adverse events, biomarkers, mental healthhttps://mindmedicinelaw.com/briefing/dea-s-federal-rescheduling-questions-implications-for-psychedelics-policy-in-the-20260831-38671The Psychedelic Journalen2026-09-04T15:08:48.408064+00:00DEA’s Federal Rescheduling Questions: Implications for Psychedelics Policy in the U.S.dea marijuana rescheduling, psychedelics policy, federal regulation, controlled substances act, compliance requirements, clinical research, registration process, diversion controls, legal implications, future of psychedelicshttps://mindmedicinelaw.com/briefing/motivation-reward-context-and-control-implications-for-psychedelic-research-20260831-38082The Psychedelic Journalen2026-09-03T15:04:29.193879+00:00Motivation, Reward Context, and Control: Implications for Psychedelic Researchmotivation, controllability, reward context, depression, psychedelic research, behavioral paradigms, clinical trials, effort allocation, drift diffusion modelinghttps://mindmedicinelaw.com/briefing/ketamine-induced-memory-dysfunction-mechanisms-and-clinical-policy-implications-20260830-38651The Psychedelic Journalen2026-09-04T15:09:02.451023+00:00Ketamine-Induced Memory Dysfunction: Mechanisms and Clinical Policy Implicationsketamine, memory dysfunction, NMDA receptor, synaptic plasticity, clinical protocols, policy implications, cognitive side effects, psychiatric treatment, regulatory guidancehttps://mindmedicinelaw.com/briefing/systematic-review-of-ketamine-and-esketamine-for-trd-evidence-and-implications-20260830-38100The Psychedelic Journalen2026-09-03T15:04:38.428654+00:00Systematic Review of Ketamine and Esketamine for TRD: Evidence and Implicationsketamine, esketamine, treatment-resistant depression, systematic review, antidepressant efficacy, safety profile, clinical guidelines, regulatory policy, psychedelic research, NMDA receptor